Elan's Response to FASB
Executive Summary
While the Federal Accounting Standards Board has basically ruled out the kinds of limited partnerships Elan for years used to finance its R&D off its income statement, a new set of deals show just how Elan is using deals with biotechs and other drug delivery companies to both supplement its research program and spare its P&L.